Cochrane Abstracts
Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside or nucleotide‐reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral‐naïve individuals Unchanged
Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside or nucleotide‐reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral‐naïve individuals Unchanged is a topic covered in the Cochrane Abstracts.
To view the entire topic, please log in or purchase a subscription.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:
There's more to see -- the rest of this entry is available only to subscribers.
Citation
"Efavirenz or Nevirapine in Three‐drug Combination Therapy With Two Nucleoside or Nucleotide‐reverse Transcriptase Inhibitors for Initial Treatment of HIV Infection in Antiretroviral‐naïve Individuals Unchanged." Cochrane Abstracts, Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/435420/all/Efavirenz_or_nevirapine_in_three‐drug_combination_therapy_with_two_nucleoside_or_nucleotide‐reverse_transcriptase_inhibitors_for_initial_treatment_of_HIV_infection_in_antiretroviral‐naïve_individuals_Unchanged. Accessed 24 January 2021.
Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside or nucleotide‐reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral‐naïve individuals Unchanged. Cochrane Abstracts. https://evidence.unboundmedicine.com/evidence/view/Cochrane/435420/all/Efavirenz_or_nevirapine_in_three‐drug_combination_therapy_with_two_nucleoside_or_nucleotide‐reverse_transcriptase_inhibitors_for_initial_treatment_of_HIV_infection_in_antiretroviral‐naïve_individuals_Unchanged. Accessed January 24, 2021.
Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside or nucleotide‐reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral‐naïve individuals Unchanged. In Cochrane Abstracts Retrieved January 24, 2021, from https://evidence.unboundmedicine.com/evidence/view/Cochrane/435420/all/Efavirenz_or_nevirapine_in_three‐drug_combination_therapy_with_two_nucleoside_or_nucleotide‐reverse_transcriptase_inhibitors_for_initial_treatment_of_HIV_infection_in_antiretroviral‐naïve_individuals_Unchanged
Efavirenz or Nevirapine in Three‐drug Combination Therapy With Two Nucleoside or Nucleotide‐reverse Transcriptase Inhibitors for Initial Treatment of HIV Infection in Antiretroviral‐naïve Individuals Unchanged [Internet]. In: Cochrane Abstracts. [cited 2021 January 24]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/435420/all/Efavirenz_or_nevirapine_in_three‐drug_combination_therapy_with_two_nucleoside_or_nucleotide‐reverse_transcriptase_inhibitors_for_initial_treatment_of_HIV_infection_in_antiretroviral‐naïve_individuals_Unchanged.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside or nucleotide‐reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral‐naïve individuals Unchanged
ID - 435420
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/435420/all/Efavirenz_or_nevirapine_in_three‐drug_combination_therapy_with_two_nucleoside_or_nucleotide‐reverse_transcriptase_inhibitors_for_initial_treatment_of_HIV_infection_in_antiretroviral‐naïve_individuals_Unchanged
DB - Evidence Central
DP - Unbound Medicine
ER -
